LumiraDx (LMDX) to Release Quarterly Earnings on Wednesday

LumiraDx (NASDAQ:LMDXGet Rating) is scheduled to post its quarterly earnings results after the market closes on Wednesday, May 11th. Analysts expect LumiraDx to post earnings of ($0.02) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

LumiraDx (NASDAQ:LMDXGet Rating) last released its earnings results on Thursday, March 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.01). The firm had revenue of $118.25 million during the quarter, compared to the consensus estimate of $119.00 million. On average, analysts expect LumiraDx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:LMDX opened at $4.47 on Wednesday. The company has a current ratio of 2.81, a quick ratio of 1.78 and a debt-to-equity ratio of 1.85. LumiraDx has a 1 year low of $4.01 and a 1 year high of $11.09. The business has a fifty day simple moving average of $6.10 and a 200 day simple moving average of $7.98.

A number of hedge funds and other institutional investors have recently bought and sold shares of LMDX. UBS Group AG bought a new position in LumiraDx during the third quarter valued at about $29,000. Penserra Capital Management LLC bought a new position in LumiraDx during the fourth quarter valued at about $31,000. Morgan Stanley bought a new position in LumiraDx during the third quarter valued at about $75,000. Susquehanna International Group LLP bought a new position in LumiraDx during the fourth quarter valued at about $89,000. Finally, Geode Capital Management LLC bought a new position in LumiraDx during the third quarter valued at about $205,000.

Several analysts recently issued reports on LMDX shares. Zacks Investment Research upgraded LumiraDx from a “sell” rating to a “hold” rating in a report on Wednesday. Raymond James cut their price objective on LumiraDx from $13.00 to $9.00 and set an “outperform” rating for the company in a report on Friday, March 11th.

About LumiraDx (Get Rating)

LumiraDx Limited operates as a point of care diagnostic company. It focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. The company was formerly known as Point of Care Testing Limited and changed its name to LumiraDx Ltd in January 2018.

Further Reading

Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.